In vitro and in vivo studies confirm the tumor-suppressive effects of resveratrol, suggesting its potential as a therapeutic agent targeting RBM15-dependent pathways in ccRCC. This evidence concerns the gene RBM15 and nonpapillary renal cell carcinoma.